Giuseppe Lamberti
University of Bologna
Publications 20
#1Francesco GelsominoH-Index: 12
#2Giuseppe LambertiH-Index: 2
Last.Andrea ArdizzoniH-Index: 45
view all 0 authors...
Abstract Small cell lung cancer (SCLC) was defined as a “recalcitrant cancer” because of its dismal prognosis and lack of outcome improvements in the last 30 years. Immunotherapy with checkpoint inhibitors revolutionized treatment in many cancer types and results from the IMpower133 study, a double-blind placebo-controlled phase III trial, showed overall-survival benefit for atezolizumab when added to standard platinum-etoposide chemotherapy in first-line SCLC setting for the first time since ye...
#1Nicole Brighi (UNIBO: University of Bologna)H-Index: 5
#2Giuseppe Lamberti (UNIBO: University of Bologna)H-Index: 2
Last.Davide Campana (UNIBO: University of Bologna)H-Index: 22
view all 3 authors...
Activating epidermal growth factor receptor ( EGFR ) mutations are reported in 30–40% of Asiatic patients and in 10–15% of unselected Caucasian patients with advanced non-small cell lung cancer (NSCLC) (1).